Lantheus delivered a solid third quarter in 2025 with worldwide revenue reaching $384.0 million and free cash flow of $94.7 million. The company also announced a leadership transition, completed the acquisition of Life Molecular Imaging, and advanced several key pipeline products with upcoming PDUFA dates.

Lantheus experienced a slight decline in worldwide revenue in Q2 2025, primarily due to decreased PYLARIFY sales amidst increased competition. However, the company saw significant growth in GAAP net income and EPS. Strategic acquisitions of Life Molecular Imaging and Evergreen Theragnostics were completed, expanding the company's portfolio and capabilities. A new $400 million stock repurchase program was also authorized, reflecting confidence in long-term strategy.

Lantheus delivered $372.8 million in revenue and $1.53 in non-GAAP EPS for Q1 2025, with strong free cash flow and continued strategic investments through acquisitions.

Lantheus reported worldwide revenue of $391.1 million for Q4 2024, a 10.5% increase compared to the same period in 2023. PYLARIFY achieved record net sales, but the company posted a GAAP net loss of $11.8 million for the quarter. Adjusted earnings per share were $1.59, reflecting continued growth in radiopharmaceuticals.

Lantheus reported a strong Q3 2024 with an 18.4% increase in worldwide revenue to $378.7 million. GAAP EPS was $1.79, while adjusted EPS was $1.70. The company is narrowing its full-year 2024 revenue and EPS guidance towards the higher end of previous estimates.

Lantheus reported a strong second quarter with worldwide revenue of $394.1 million, a 22.5% increase from Q2 2023. Growth was primarily driven by PYLARIFY and DEFINITY. The company completed three strategic transactions to expand its radiopharmaceutical pipeline. GAAP fully diluted earnings per share were $0.88, while adjusted fully diluted earnings per share were $1.80.

Lantheus Holdings, Inc. reported a strong first quarter in 2024, with worldwide revenue increasing by 23.0% to $370.0 million. GAAP fully diluted net income per share was $1.87, compared to a loss of $0.04 in the same period last year. The company has raised its full-year 2024 revenue and earnings guidance.

Lantheus Holdings, Inc. reported a strong Q4 2023 with worldwide revenue of $354.0 million, a 34.5% increase compared to Q4 2022. GAAP net income was $103.4 million, or $1.47 per fully diluted share, compared to a net loss in the prior year. Adjusted fully diluted EPS was $1.75, a 28.0% increase year-over-year. Free cash flow was $100.2 million.

Lantheus reported strong Q3 2023 financial results, with a significant increase in worldwide revenue and GAAP net income compared to the same period last year. The company's performance was driven by its commercial portfolio and pipeline progress.

Lantheus reported a strong second quarter in 2023, with worldwide revenue of $321.7 million, representing a 43.8% increase from the prior year period. GAAP net income was $94.1 million, or $1.33 per fully diluted share, compared to $43.1 million, or $0.61 per fully diluted share, in the prior year period. Adjusted fully diluted net income per share was $1.54, compared to $0.89 in the prior year period.

Lantheus Holdings, Inc. reported a worldwide revenue increase of 44.0% year-over-year, reaching $300.8 million. The company experienced a GAAP net loss of $2.8 million, or $0.04 per fully diluted share, but achieved an adjusted fully diluted net income per share of $1.47. Free cash flow was $99.3 million, marking a significant increase from the prior year period.

Lantheus reported a substantial increase in revenue and a return to profitability for Q4 2022. Worldwide revenue increased by 103.1% compared to the prior year period, driven primarily by the strong performance of PYLARIFY. The company achieved an adjusted fully diluted EPS of $1.37, a significant increase from $0.25 in the prior year period.

Lantheus reported a significant increase in revenue and a shift to net income in Q3 2022. Worldwide revenue increased by 134.4% compared to the prior year period, and GAAP net income was $61.2 million, compared to a net loss in the prior year period. The company also provided Q4 2022 revenue and adjusted diluted EPS guidance and increased full year guidance.

Lantheus reported a worldwide revenue of $223.7 million for Q2 2022, a 121.4% increase from the prior year period. GAAP net income was $43.1 million, or $0.61 per fully diluted share, compared to a net loss of $26.7 million, or $0.39 per fully diluted share, in the prior year period. Adjusted fully diluted earnings per share were $0.89, compared to $0.11 for the same period last year. Free cash flow was $68.3 million, representing an increase of approximately $45.0 million from the prior year period.

Lantheus Holdings, Inc. reported a significant increase in revenue and earnings for the first quarter of 2022. Worldwide revenue increased by 125.8% compared to the prior year, with a substantial rise in GAAP net income and adjusted fully diluted EPS. The company's performance was primarily driven by rapidly increasing PYLARIFY sales and strategic partnerships.

Lantheus Holdings, Inc. reported a worldwide revenue of $101.1 million for Q2 2021, a 53.1% increase compared to the prior year period. The company's GAAP net loss was $26.7 million, or $0.39 per fully diluted share, while adjusted fully diluted EPS was $0.11. Net cash from operating activities was $25.9 million, and free cash flow was $23.2 million.

Lantheus Holdings, Inc. reported a 2.0% increase in worldwide revenue, reaching $92.5 million for Q1 2021. Net income increased to $9.0 million, with GAAP EPS at $0.13. Free cash flow was $7.3 million for the quarter.

Lantheus Holdings, Inc. reported a 5.4% increase in worldwide revenue for the fourth quarter of 2020, totaling $94.2 million, compared to $89.3 million in the prior year period. The company's net loss for the quarter was $3.4 million, or $0.05 per fully diluted share, compared to a net income of $10.5 million, or $0.26 per fully diluted share, for the fourth quarter of 2019.

Lantheus Holdings, Inc. reported a 3.2% increase in worldwide revenue for Q3 2020, totaling $88.5 million. However, the company experienced a net loss of $6.4 million, or $(0.10) per share, compared to a net income of $4.9 million, or $0.12 per share, in Q3 2019. Adjusted EPS was $0.04, down from $0.28 in the prior year period. Free cash flow for the quarter was $4.8 million.

Lantheus Holdings, Inc. reported a decrease in worldwide revenue of 23.0% compared to the prior year period. The company had a net loss of $7.0 million, or $(0.16) per fully diluted share, as compared to net income of $6.4 million, or $0.16 per fully diluted share for the second quarter of 2019. They completed the acquisition of Progenics in June.

Lantheus Holdings, Inc. reported a 4.8% increase in worldwide revenue for Q1 2020, totaling $90.7 million. Net income decreased by 66.5% to $3.3 million, with GAAP diluted EPS down 66.7% to $0.08. However, adjusted diluted EPS increased by 26.1% to $0.36. The company's free cash flow was $6.7 million. Due to the uncertain impact of COVID-19, Lantheus has withdrawn its 2020 guidance.

Lantheus Holdings, Inc. reported a 3.6% increase in worldwide revenue for the fourth quarter of 2019, totaling $89.3 million. Net income for the quarter was $10.5 million, a decrease of 21.4% compared to the same period in 2018. Adjusted fully diluted earnings per share were $0.34, representing a 19.0% increase over the prior year period. The company provided first quarter and full year 2020 revenue and adjusted fully diluted earnings per share guidance.